Selective toxicity of
dihydroartemisinin and holotransferrin toward human
breast cancer cells.
Artemisinin becomes cytotoxic in
the presence of ferrous iron. Since iron influx is
high in cancer cells, artemisinin and its analogs
selectively kill cancer cells under conditions that
increase intracellular iron concentrations. We report
here that after incubation with holotransferrin, which
increases the concentration of ferrous iron in cancer
cells, dihydroartemisinin, an analog of artemisinin,
effectively killed a type of radiation-resistant human
breast cancer cell in vitro. The same treatment had
considerably less effect on normal human breast cells.
Since it is relatively easy to increase the iron
content inside cancer cells in vivo, administration of
artemisinin-like drugs and intracellular
iron-enhancing compounds may be a simple, effective,
and economical treatment for cancer. 11/30/2001;
Life Sciences
Artesunate,
Integrated Safety
Rosemary Johann-Liang, M.D. Division of Special
Pathogen and Immunological Drug Products
Qinghaosu
(ARTEMISININ)
Artemisinin was originally developed in 1972 in
China (Chines Institute of material medicine) from
the plant ..................
Herb-based
Anti-malaria Drug
Center of International Dispute - McNeil Jr. DG. New Drug for Malaria Pits U.S.
Against Africa. New York Times May 28, 2002.
ALWAYS BEING UPDATED
Copyright (c) 2001-2012
- SimpleCure.Com - All Rights Reserved